Αναστασία Κωνσταντινίδου
ΚΩΝΣΤΑΝΤΙΝΙΔΟΥ ΑΝΑΣΤΑΣΙΑ
CONSTANTINIDOU ANASTASIA
...
-
Medical School
-
-
-
-
-
-

Προσωπικό Προφίλ

 
Dr Anastasia Constantinidou graduated with a first class from the Medical School of the National and Kapodistrian University in Athens Greece (MD). She gained Membership of the Royal College of Physicians (MRCP) in the UK and she subsequently completed her specialist clinical training in Internal Medicine and her specialist clinical training in Medical Oncology (CCT) at the Royal Marsden Hospital in London (2011). She gained an MSc in Oncology (Merit) from the University of London and she was awarded a Wellcome Trust Fellowship for laboratory research in Molecular Pathology for her four-year full time PhD studies at the Institute of Cancer Research, University of London.

Her basic science research has focused on the identification of genes involved in the process of cell differentiation as novel targets in cancer therapeutics with emphasis on epigenetics. Her clinical and translational research expertise is based on first-hand experience in running over 80 UK, European and international clinical and translational trials as a principal or co-investigator including first in human (phase I) clinical trials.

She has been awarded a number of fellowships throughout her career including the Hellenic Society of Medical Oncology Clinical Training Fellowship and the ECCO-AACR-EORTC-ESMO Fellowship in Methods in Clinical Cancer Research Workshop as well as grants from the Wellcome Trust UK, the Sarcoma UK, the Research and Innovation Foundation (RIF Cyprus), the Horizon 2020 Research and Innovation Framework European Programme. She was the recipient of the 2020 Young Investigator Award in Life Sciences by the RIF.

Through competitive selection, she has presented her work in many international conferences including the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO) and the Connective Tissue Oncology Society (CTOS) annual conferences for over a decade. She has authored publications in high impact factor peer-reviewed journals including the Lancet Oncology, the Nature Reviews Clinical Oncology, the Annals of Oncology, the European Journal of Cancer, the British Journal of Cancer and Pharmacology & Therapeutics.

She serves as a reviewer and an editorial board member in oncology and medical journals. She has been an invited speaker and chair on topics related to her research and clinical work nationally (UK, Cyprus) and internationally. She has served as an invited organizing committee member in the 2019 annual ESMO Asia and the 2020 annual ESMO conferences. She has been a Faculty member of the European School of Oncology (Southern Europe and Arab Countries) Meeting for oncology trainees and junior oncologists, since 2017 and she serves as the local chair in 2021.

Dr Constantinidou is the coordinator of the first postgraduate programme of the Medical School of the UCY, entitled Precision Medicine in Clinical Practice, which will enrol its first students in September 2021. She is a member of the National (Cyprus) Bioethics Committee and the National (Cyprus) Committee for Laboratory Animal Welfare since 2018. She is the coordinator of the Bank of Cyprus Oncology Centre team serving as a National Affiliated Centre of the European Reference Network EURACAN Rare Adult Solid Cancers. She also serves as the Secretary of the Cyprus Oncology Society since 2019 and the Representative of Cyprus in the ESMO National Societies Committee.

Ø  translational research applications with emphasis on the utilization of laboratory discoveries related to gene expression to identify new targets for anticancer therapy and biomarkers to guide response assessment in the context of personalized and precision medicine

Ø  early phase clinical trials of novel targeted agents in cancer

Ø  the role of genetic and epigenetic changes in cancer development and progression and  the potential of these changes to become targets for therapy

Ø  functional imaging in humans and its role in the assessment of biological changes during disease progression



Selected peer reviewed publications
  • Chatzittofis A, Karanikola M, Michailidou K, Constantinidou A. Impact of the COVID-19 Pandemic on the Mental Health of Healthcare Workers. Int J Environ Res Public Health. 2021 Feb 3;18(4):1435.
  • Guo C, Chénard-Poirier M, Roda D, de Miguel M, Harris SJ, Candilejo IM, Sriskandarajah P, Xu W, Scaranti M, Constantinidou A, King J, Parmar M, Turner AJ, Carreira S, Riisnaes R, Finneran L, Hall E, Ishikawa Y, Nakai K, Tunariu N, Basu B, Kaiser M, Lopez JS, Minchom A, de Bono JS, Banerji U. Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study. Lancet Oncol. 2020 Nov;21(11):1478-1488.
  • Hadjipanteli A, Doolan P, Kyriacou E, Constantinidou A. Breast Cancer Brain Metastasis: The Potential Role of MRI Beyond Current Clinical Applications. Cancer Manag Res. 2020 Oct 12;12:9953-9964.
  • Constantinidou A, Sauve N, Stacchiotti S, Blay JY, Vincenzi B, Grignani G, Rutkowski P, Guida M, Hindi N, Klein A, Thibaud V, Sufliarsky J, Desar I, Steeghs N, Litiere S, Gelderblom H, Jones RL. Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study. ESMO Open. 2020 Aug;5(4):e000787.
  • Farag S, Smith MJ, Fotiadis N, Constantinidou A *, Jones RL *. Revolutions in treatment options in gastrointestinal stromal tumours (GISTs): the latest updates. Curr Treat Options Oncol. 2020 May 27;21(7):55.
  • Gkolfinopoulos S, Jones RL, Constantinidou A. The Emerging Role of Platelets in the Formation of the Micrometastatic Niche: Current Evidence and Future Perspectives. Front Oncol. 2020 Mar 18;10:374.
  • Filippou PS, Karagiannis GS, Constantinidou A. Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target. Oncogene. 2020 Mar;39(10):2040-2054.
  • Panayides AS, Pattichis MS, Leandrou S, Pitris C, Constantinidou A, Pattichis CS. Radiogenomics for Precision Medicine With a Big Data Analytics Perspective. IEEE J Biomed Health Inform. 2019 Sep;23(5):2063-2079.
  • A. Constantinidou, C. Alifieris, D. T Trafalis. Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A prosperous new era in cancer active immunotherapy. Pharmacology & Therapeutics. 2019 Feb;194:84-106.
  • Chrysostomou AC, Stylianou DC, Constantinidou A, Kostrikis LG. Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing. Viruses. 2018 Dec 19;10(12).
  • Constantinidou A, Jones L R. Systemic Therapy in RPS Management. J Surg Oncol. 2018 Jan;117(1):87-92.
  • Constantinidou A, van der Graaf WTA. The fate of new fosfamides in phase III studies in advanced soft tissue sarcoma. Eur J Cancer. 2017 Oct;84:257-261. 
  • Szucs Z, Thway K, Fisher C, Bulusu R, Constantinidou A, Benson C, van der Graaf WT, Jones RL. Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications. Future Oncol. 2017 Jan;13(1):93-107
  • Desar IM, Constantinidou A, Kaal SE, Jones RL, van der Graaf WT. Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin. Cancer Manag Res. 2016 Aug 17;8:95-104.
  • A Constantinidou, I R Judson. Systemic treatment of liposarcomas: light at the end of the tunnel? J Oncol Pract. 2016 Mar;12(3):228-9.
    Noujaim J, Constantinidou A, Messiou C, Thway K, Miah A, Benson C, Judson I, Jones RL. Successful Ifosfamide Rechallenge in Soft-Tissue Sarcoma. Am J Clin Oncol. 2015 Oct 29.
  • Sanfilippo R, Dileo P, Blay JY, Constantinidou A, Le Cesne A, Benson C, Vizzini L, Contu M, Baldi GG, Dei Tos AP, Casali PG. Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network. Anticancer Drugs. 2015 Jul;26(6):678-81.
  • Constantinidou A, Pollack SM, Jones RL. Management and outcome of metastatic clear cell sarcoma. Eur J Surg Oncol. 2014 Oct;40(10):1383.
  • J Martin-Liberal, S Alam, A Constantinidou, C Fisher, K Khabra, C Messiou, D Olmos, S Mitchell, O Al-Muderis, A Miah, M Linch, R L. Jones, M Scurr, I Judson, and C Benson. Clinical activity and tolerability of a 14-day infusional ifosfamide schedule in soft-tissue sarcoma. Hindawi Publishing Corporation. Sarcoma. 2013: 868973.
  • A Constantinidou, A Miah, S Pollack, RL Jones. New Drugs and clinical trial design in advanced Sarcoma: have we made any progress? Future Oncol. 2013 Oct;9(10):1409-11. doi: 10.2217/fon.13.132. Epub 2013 Jul 15.
  • AJ Bathan*, A Constantinidou*, SM Pollack, RL Jones. Diagnosis, prognosis, and management of Leiomyosarcoma: recognition of anatomic variants. Curr Opin Oncol. 2013 Jul;25(4):384-9.
  • Constantinidou A, Pollack S, Loggers E, Rodler E, Jones RL. The evolution of systemic therapy in sarcoma. Expert Rev Anticancer Ther. 2013 Feb;13(2):211-23.
  • A Constantinidou, D Cunningham, F Shurmahi, U Asghar, Y Barbachano, A Khan, S Mudan, S Rao, I Chau. Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection. Clin Colorectal Cancer. 2013 Mar;12(1):15-22.
  • B Sharma, A Martin, S Stanway, S R D Johnston and A Constantinidou. Imaging in oncology - over a century of advances. Nat Rev Clin Oncol. 2012 Dec;9(12):728-37.
  • A Constantinidou, SM Pollack, RL Jones. MDM2 inhibition in well- and de-differentiated liposarcoma: A step in the right direction. Lancet Oncol. 2012 Nov;13(11):1070-1.
  • R L Jones, A Constantinidou, J S Reis-Filho. Molecular Classification of Breast Cancer. Surg Pathol Clin. 2012 Sep;5(3):701-17.
    Constantinidou A, Smith I. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer? Breast 2011 Oct; 20 Suppl 3:S158-61.
  • Constantinidou A, Jones R L, D Olmos D, Thway K, Fisher C, Al-Muderis O, Judson I. Conventional anthracycline-based chemotherapy has limited efficacy in Solitary Fibrous Tumour. Acta Oncol. 2012 Apr;51(4):550-4.
  • RL Jones, A Constantinidou, D Olmos, K Thway, C Fisher, O Al-Muderis, M Scurr, I Judson. Role of palliative chemotherapy in advanced epithelioid sarcoma. Am J Clin Oncol. 2012 Aug;35(4):351-7.
  • Waddell T*, Kotsori A*, Constantinidou A, Yousaf N, Ashley S, Parton M, Allen M, Starling N, Papadopoulos P, O'Brien M, Smith I, Johnston S. Trastuzumab beyond progression in HER2-positive advanced breast cancer: The Royal Marsden experience. Br J Cancer. 2011 May 24;104(11):1675-9.
  • A Constantinidou, R L Jones, M Scurr, O Al-Muderis, I Judson. Aggressive fibromatosis: effective palliation with chemotherapy. Acta Oncol. 2011 Apr;50(3):455-61.
  • A Constantinidou, A Martin, B Sharma, S Johnston. Positron Emission Tomography/ Computed Tomography in the management of recurrent/ metastatic breast cancer: a large retrospective study from the Royal Marsden Hospital. Ann Oncol. 2011 Feb 22 ;(2): 307-314.
  • A. Constantinidou, R. L. Jones, Jorge S Reis-Filho. Beyond triple-negative breast cancer - the need to define new subtypes. Expert Rev of Anticancer Ther. 2010 Aug; 10(8): 1197-213.
  • A. Constantinidou, S.A. Afuwape, L. Linsell, T. Hung, K. Acland, C. Healy, A-J Ramirez, M. Harries. Informational needs of patients with melanoma and their views on the utility of investigative tests. Int J Clin Pract. 2009 Nov;63(11):1595-600.
  • A. Constantinidou, R. L. Jones, M. Scurr, O. Al-Muderis, I. Judson. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. Eur J Cancer. 2009 Nov;45(17):2930-4
  • Constantinidou A, Hofman M, O’Doherty M, Acland KM, Healy C, Harries M. Routine positron emission tomography and positron emission tomography/computed tomography in melanoma staging with positive sentinel node biopsy is of limited benefit. Melanoma Res. 2008 Feb; 18(1):56-60.
     

Profile Information

 Dr Anastasia Constantinidou graduated with a first class from the Medical School of the National and Kapodistrian University in Athens Greece (MD). She gained Membership of the Royal College of Physicians (MRCP) in the UK and she subsequently completed her specialist clinical training in Internal Medicine and her specialist clinical training in Medical Oncology (CCT) at the Royal Marsden Hospital in London (2011). She gained an MSc in Oncology (Merit) from the University of London and she was awarded a Wellcome Trust Fellowship for laboratory research in Molecular Pathology for her four-year full time PhD studies at the Institute of Cancer Research, University of London.
 
Her basic science research has focused on the identification of genes involved in the process of cell differentiation as novel targets in cancer therapeutics with emphasis on epigenetics. Her clinical and translational research expertise is based on first-hand experience in running over 80 UK, European and international clinical and translational trials as a principal or co-investigator including first in human (phase I) clinical trials.
 
She has been awarded a number of fellowships throughout her career including the Hellenic Society of Medical Oncology Clinical Training Fellowship and the ECCO-AACR-EORTC-ESMO Fellowship in Methods in Clinical Cancer Research Workshop as well as grants from the Wellcome Trust UK, the Sarcoma UK, the Research and Innovation Foundation (RIF Cyprus), the Horizon 2020 Research and Innovation Framework European Programme. She was the recipient of the 2020 Young Investigator Award in Life Sciences by the RIF. 
 
Through competitive selection, she has presented her work in many international conferences including the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO) and the Connective Tissue Oncology Society (CTOS) annual conferences for over a decade. She has authored publications in high impact factor peer-reviewed journals including the Lancet Oncology, the Nature Reviews Clinical Oncology, the Annals of Oncology, the European Journal of Cancer, the British Journal of Cancer and Pharmacology & Therapeutics. 
 
She serves as a reviewer and an editorial board member in oncology and medical journals. She has been an invited speaker and chair on topics related to her research and clinical work nationally (UK, Cyprus) and internationally. She has served as an invited organizing committee member in the 2019 annual ESMO Asia and the 2020 annual ESMO conferences. She has been a Faculty member of the European School of Oncology (Southern Europe and Arab Countries) Meeting for oncology trainees and junior oncologists, since 2017 and she serves as the local chair in 2021.
 
Dr Constantinidou is the coordinator of the first postgraduate programme of the Medical School of the UCY, entitled Precision Medicine in Clinical Practice, which will enrol its first students in September 2021. She is a member of the National (Cyprus) Bioethics Committee and the National (Cyprus) Committee for Laboratory Animal Welfare since 2018. She is the coordinator of the Bank of Cyprus Oncology Centre team serving as a National Affiliated Centre of the European Reference Network EURACAN Rare Adult Solid Cancers. She also serves as the Secretary of the Cyprus Oncology Society since 2019 and the Representative of Cyprus in the ESMO National Societies Committee.  
 
Ø  translational research applications with emphasis on the utilization of laboratory discoveries related to gene expression to identify new targets for anticancer therapy and biomarkers to guide response assessment in the context of personalized and precision medicine

Ø  early phase clinical trials of novel targeted agents in cancer

Ø  the role of genetic and epigenetic changes in cancer development and progression and  the potential of these changes to become targets for therapy

Ø  functional imaging in humans and its role in the assessment of biological changes during disease progression

Selected peer reviewed publications

  • Chatzittofis A, Karanikola M, Michailidou K, Constantinidou A. Impact of the COVID-19 Pandemic on the Mental Health of Healthcare Workers. Int J Environ Res Public Health. 2021 Feb 3;18(4):1435.
  • Guo C, Chénard-Poirier M, Roda D, de Miguel M, Harris SJ, Candilejo IM, Sriskandarajah P, Xu W, Scaranti M, Constantinidou A, King J, Parmar M, Turner AJ, Carreira S, Riisnaes R, Finneran L, Hall E, Ishikawa Y, Nakai K, Tunariu N, Basu B, Kaiser M, Lopez JS, Minchom A, de Bono JS, Banerji U. Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study. Lancet Oncol. 2020 Nov;21(11):1478-1488.
  • Hadjipanteli A, Doolan P, Kyriacou E, Constantinidou A. Breast Cancer Brain Metastasis: The Potential Role of MRI Beyond Current Clinical Applications. Cancer Manag Res. 2020 Oct 12;12:9953-9964.
  • Constantinidou A, Sauve N, Stacchiotti S, Blay JY, Vincenzi B, Grignani G, Rutkowski P, Guida M, Hindi N, Klein A, Thibaud V, Sufliarsky J, Desar I, Steeghs N, Litiere S, Gelderblom H, Jones RL. Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study. ESMO Open. 2020 Aug;5(4):e000787.
  • Farag S, Smith MJ, Fotiadis N, Constantinidou A *, Jones RL *. Revolutions in treatment options in gastrointestinal stromal tumours (GISTs): the latest updates. Curr Treat Options Oncol. 2020 May 27;21(7):55.
  • Gkolfinopoulos S, Jones RL, Constantinidou A. The Emerging Role of Platelets in the Formation of the Micrometastatic Niche: Current Evidence and Future Perspectives. Front Oncol. 2020 Mar 18;10:374.
  • Filippou PS, Karagiannis GS, Constantinidou A. Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target. Oncogene. 2020 Mar;39(10):2040-2054.
  • Panayides AS, Pattichis MS, Leandrou S, Pitris C, Constantinidou A, Pattichis CS. Radiogenomics for Precision Medicine With a Big Data Analytics Perspective. IEEE J Biomed Health Inform. 2019 Sep;23(5):2063-2079.
  • A. Constantinidou, C. Alifieris, D. T Trafalis. Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A prosperous new era in cancer active immunotherapy. Pharmacology & Therapeutics. 2019 Feb;194:84-106.
  • Chrysostomou AC, Stylianou DC, Constantinidou A, Kostrikis LG. Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing. Viruses. 2018 Dec 19;10(12).
  • Constantinidou A, Jones L R. Systemic Therapy in RPS Management. J Surg Oncol. 2018 Jan;117(1):87-92.
  • Constantinidou A, van der Graaf WTA. The fate of new fosfamides in phase III studies in advanced soft tissue sarcoma. Eur J Cancer. 2017 Oct;84:257-261. 
  • Szucs Z, Thway K, Fisher C, Bulusu R, Constantinidou A, Benson C, van der Graaf WT, Jones RL. Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications. Future Oncol. 2017 Jan;13(1):93-107
  • Desar IM, Constantinidou A, Kaal SE, Jones RL, van der Graaf WT. Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin. Cancer Manag Res. 2016 Aug 17;8:95-104.
  • A Constantinidou, I R Judson. Systemic treatment of liposarcomas: light at the end of the tunnel? J Oncol Pract. 2016 Mar;12(3):228-9.
  • Noujaim J, Constantinidou A, Messiou C, Thway K, Miah A, Benson C, Judson I, Jones RL. Successful Ifosfamide Rechallenge in Soft-Tissue Sarcoma. Am J Clin Oncol. 2015 Oct 29.
  • Sanfilippo R, Dileo P, Blay JY, Constantinidou A, Le Cesne A, Benson C, Vizzini L, Contu M, Baldi GG, Dei Tos AP, Casali PG. Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network. Anticancer Drugs. 2015 Jul;26(6):678-81.
  • Constantinidou A, Pollack SM, Jones RL. Management and outcome of metastatic clear cell sarcoma. Eur J Surg Oncol. 2014 Oct;40(10):1383.
  • J Martin-Liberal, S Alam, A Constantinidou, C Fisher, K Khabra, C Messiou, D Olmos, S Mitchell, O Al-Muderis, A Miah, M Linch, R L. Jones, M Scurr, I Judson, and C Benson. Clinical activity and tolerability of a 14-day infusional ifosfamide schedule in soft-tissue sarcoma. Hindawi Publishing Corporation. Sarcoma. 2013: 868973.
  • A Constantinidou, A Miah, S Pollack, RL Jones. New Drugs and clinical trial design in advanced Sarcoma: have we made any progress? Future Oncol. 2013 Oct;9(10):1409-11. doi: 10.2217/fon.13.132. Epub 2013 Jul 15.
  • AJ Bathan*, A Constantinidou*, SM Pollack, RL Jones. Diagnosis, prognosis, and management of Leiomyosarcoma: recognition of anatomic variants. Curr Opin Oncol. 2013 Jul;25(4):384-9.
  • Constantinidou A, Pollack S, Loggers E, Rodler E, Jones RL. The evolution of systemic therapy in sarcoma. Expert Rev Anticancer Ther. 2013 Feb;13(2):211-23.
  • A Constantinidou, D Cunningham, F Shurmahi, U Asghar, Y Barbachano, A Khan, S Mudan, S Rao, I Chau. Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection. Clin Colorectal Cancer. 2013 Mar;12(1):15-22.
  • B Sharma, A Martin, S Stanway, S R D Johnston and A Constantinidou. Imaging in oncology - over a century of advances. Nat Rev Clin Oncol. 2012 Dec;9(12):728-37.
  • A Constantinidou, SM Pollack, RL Jones. MDM2 inhibition in well- and de-differentiated liposarcoma: A step in the right direction. Lancet Oncol. 2012 Nov;13(11):1070-1.
  • R L Jones, A Constantinidou, J S Reis-Filho. Molecular Classification of Breast Cancer. Surg Pathol Clin. 2012 Sep;5(3):701-17.
  • Constantinidou A, Smith I. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer? Breast 2011 Oct; 20 Suppl 3:S158-61.
  • Constantinidou A, Jones R L, D Olmos D, Thway K, Fisher C, Al-Muderis O, Judson I. Conventional anthracycline-based chemotherapy has limited efficacy in Solitary Fibrous Tumour. Acta Oncol. 2012 Apr;51(4):550-4.
  • RL Jones, A Constantinidou, D Olmos, K Thway, C Fisher, O Al-Muderis, M Scurr, I Judson. Role of palliative chemotherapy in advanced epithelioid sarcoma. Am J Clin Oncol. 2012 Aug;35(4):351-7.
  • Waddell T*, Kotsori A*, Constantinidou A, Yousaf N, Ashley S, Parton M, Allen M, Starling N, Papadopoulos P, O'Brien M, Smith I, Johnston S. Trastuzumab beyond progression in HER2-positive advanced breast cancer: The Royal Marsden experience. Br J Cancer. 2011 May 24;104(11):1675-9.
  • A Constantinidou, R L Jones, M Scurr, O Al-Muderis, I Judson. Aggressive fibromatosis: effective palliation with chemotherapy. Acta Oncol. 2011 Apr;50(3):455-61.
  • A Constantinidou, A Martin, B Sharma, S Johnston. Positron Emission Tomography/ Computed Tomography in the management of recurrent/ metastatic breast cancer: a large retrospective study from the Royal Marsden Hospital. Ann Oncol. 2011 Feb 22 ;(2): 307-314.
  • A. Constantinidou, R. L. Jones, Jorge S Reis-Filho. Beyond triple-negative breast cancer - the need to define new subtypes. Expert Rev of Anticancer Ther. 2010 Aug; 10(8): 1197-213.
  • A. Constantinidou, S.A. Afuwape, L. Linsell, T. Hung, K. Acland, C. Healy, A-J Ramirez, M. Harries. Informational needs of patients with melanoma and their views on the utility of investigative tests. Int J Clin Pract. 2009 Nov;63(11):1595-600.
  • A. Constantinidou, R. L. Jones, M. Scurr, O. Al-Muderis, I. Judson. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. Eur J Cancer. 2009 Nov;45(17):2930-4
  • Constantinidou A, Hofman M, O’Doherty M, Acland KM, Healy C, Harries M. Routine positron emission tomography and positron emission tomography/computed tomography in melanoma staging with positive sentinel node biopsy is of limited benefit. Melanoma Res. 2008 Feb; 18(1):56-60.